2|0|Public
5000|$|<b>Mepiprazole</b> (INN, BAN) (brand name Psigodal) is an {{anxiolytic}} drug of the phenylpiperazine {{group with}} additional antidepressant properties that is marketed in Spain. It {{acts as a}} 5-HT2A and α1-adrenergic receptor antagonist and inhibits the reuptake and induces the release of serotonin, dopamine, and norepinephrine to varying extents, and {{has been described as}} a serotonin antagonist and reuptake inhibitor (SARI). Controlled clinical trials of <b>mepiprazole</b> in patients with irritable bowel syndrome (IBS) were also carried out and suggested some benefits of the drug in relieving symptoms of IBS in some patients. [...] Similarly to other phenylpiperazines like trazodone, nefazodone, and etoperidone, <b>mepiprazole</b> produces mCPP as an active metabolite.|$|E
40|$|The {{effect of}} a new tranquillizer, <b>mepiprazole,</b> in the {{treatment}} of the irritable bowel syndrome has been studied in a double-blind cross-over trial in 19 patients. After examination to exclude organic disease the patients were followed up over two treatment periods of four weeks each under either placebo or the active principle, each patient being his own control. The results indicated that the drug had a beneficial effect (P < 0 · 05) provided that it was given for a period of at least three weeks...|$|E

